Skip to main content

Table 1 Effects of two different formulations of LopiGLIK® on glycemia and serum lipids

From: Does EFSA statement on Monacolin content of nutraceutical combinations impair their lipid lowering effect? The LopiGLIK experience

Serum levels

Baseline

LopiGLIK® 3.3 mg

LopiGLIK® 3 mg

Glycemia (mg/dL)

95.6 ± 7.4

91.4 ± 6.1

98.8 ± 6.8

Total-Cholesterol (mg/dL)

234.2 ± 15.1

201.2 ± 5.1*

189.3 ± 13.6*

HDL-Cholesterol (mg/dL)

54.7 ± 10.3

55.1 ± 6.2

59.9 ± 6.4

Triglycerides (mg/dL)

110.1 ± 19.5

111.2 ± 22.0

101.9 ± 24.2

LDL Cholesterol (mg/dL)

157.0 ± 14.0

123.8 ± 6.6*

109.0 ± 12.4*

  1. * = p < 0.01 vs. baseline